ArticleInternational journal of retina and vitreous2025
Changes of choroidal thickness and choroidal vascularity index in patients with macular edema secondary to branch retinal vein occlusion after intravitreal ranibizumab.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo observe the changes of choroidal thickness (CT) and choroidal vascularity index (CVI) in patients with macular edema secondary to branch retinal vein occlusion (BRVO) after multiple intravitreal injections of ranibizumab.
methodsA retrospective cohort study was conducted on 91 patients (91 eyes) with unilateral BRVO treated with a 3 + PRN (pro re nata) regimen of ranibizumab from January 2022 to March 2023. Optical coherence tomography (OCT) was used to measure central retinal thickness (CRT). Enhanced depth imaging OCT (EDI-OCT) was used to measure subfoveal CT (SFCT), nasal CT (1.5 mm from the fovea), and temporal CT (1.5 mm from the fovea) to calculate the mean CT. Choroidal images were binarized using ImageJ software to quantify the luminal area (LA), stromal area (SA), and total choroidal area (TCA), from which CVI (LA/TCA) was calculated. These parameters were evaluated at baseline and 1 month after each injection and were compared across different types of macular edema and between the acute and stable phases of BRVO.
resultsAt baseline, the cystoid macular edema (CME) group had significantly lower CRT and SFCT compared to the diffuse retinal thickening (DRT) and mixed-type groups (P < 0.01); however, best-corrected visual acuity (BCVA) and CVI did not differ significantly among the groups. In BRVO-affected eyes, CT, LA, SA, TCA, and CVI were all significantly higher than in contralateral eyes (P < 0.01). Compared to baseline, CT decreased significantly after the first injection and stabilized after the second (P < 0.01). CVI decreased significantly after the second injection and remained stable thereafter (P < 0.01). These changes persisted for at least six months after the final injection.
conclusionsBRVO affects both retinal and choroidal structures. BRVO-affected eyes exhibit choroidal vasodilation, stromal thickening, and have higher CT and CVI values compared to unaffected eyes. Anti-VEGF therapy effectively reduces CT and CVI during the acute phase, leading to a stable state. CVI values do not appear to differ based on the morphological type of macular edema.
trial registrationChiCTR2400090054. Registered on 13 November 2023, retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.